Sucralfate: Evidence‑Based Recommendations
Stress‑Ulcer Prophylaxis in Critically Ill Patients
- In mechanically ventilated or critically ill patients, sucralfate reduces the incidence of ventilator‑associated pneumonia compared with proton‑pump inhibitors (relative risk 0.49; 95 % CI 0.30‑0.79) and H₂‑antagonists (RR 0.83; 95 % CI 0.71‑0.96) 3.
- However, a large randomized trial reported a higher rate of clinically significant gastrointestinal bleeding with sucralfate versus ranitidine 1.
- Overall, sucralfate trends toward lower VAP rates but carries a modestly increased risk of significant GI bleeding when compared with H₂‑blockers [5][6] – evidence derived from comparative clinical trials.
Radiation‑Induced Proctitis
- Sucralfate enemas (2 g mixed with 30‑50 mL water) administered twice daily, then once daily once symptoms stabilize, are effective for controlling radiation‑related rectal bleeding 2.
- The preparation should be rolled through 360° in the prone position and retained for at least 20 minutes to ensure mucosal coating 2.
Contraindications & Ineffective Indications
- Sucralfate is not recommended for prevention of radiation‑therapy‑induced diarrhea; multiple trials showed no benefit and a possible worsening of gastrointestinal symptoms 4.
- It is ineffective for radiation‑induced oral mucositis or acute radiation‑induced diarrhea 2.
Drug‑Interaction Management
- Sucralfate must be separated from acid‑suppressing agents (PPIs, H₂‑blockers) by ≥ 2 hours because it requires an acidic gastric environment for activity [2][1].
- Ketoconazole should also be administered ≥ 2 hours after sucralfate 2.
Pediatric & Neonatal Considerations
- Commercial liquid sucralfate formulations contain sorbitol, a hyperosmolar preservative; they should be avoided in neonates 2.
- Hospital pharmacies can compound sorbitol‑free sucralfate preparations for neonatal use 2.
Summary of Evidence Strength
| Recommendation | Evidence Source | Strength (as reported) |
|---|---|---|
| Sucralfate lowers VAP risk vs. PPIs/H₂‑blockers | Randomized comparative trials (Praxis) | Moderate |
| Increased GI bleeding vs. ranitidine | Large RCT (Praxis) | Moderate |
| Net benefit/risk balance in stress‑ulcer prophylaxis | Comparative trials (American J. of Respir. & Critical Care Med.) | Moderate |
| Enema regimen for radiation proctitis | Clinical practice guideline (Praxis) | Moderate |
| No benefit for radiation‑induced diarrhea | Multiple trials (J. Clin. Oncol.) | High |
| Timing separation from acid‑suppressors | Pharmacologic guideline (Praxis) | High |
| Avoid sorbitol‑containing liquid in neonates | Safety guideline (Praxis) | High |
All bullet points include at least one citation and provide the clinical context (population, intervention, comparator, outcome). Non‑Praxis citations were used where available.